##SAMPLE=<ID=Normal1,IsTumor=no>
##SAMPLE=<ID=Tumor1,IsTumor=yes>
##ANALYSISTYPE=SOMATIC_PAIR
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample Tumor1).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample Tumor1).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample Normal1).
##DESCRIPTION=normal_dp=Normal depth (Sample Normal1).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, NM number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=ihdb_hom=Homozygous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_het=Heterozyous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_wt=Wildtype variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=General gene information from the NGSD.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##FILTER=fv.not_cod_spli=Not a coding or splicing variant (filter_vcf).
##FILTER=fv.off_target=Variant is off target (filter_vcf).
##FILTER=fv.somca_all_freq=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=fv.somca_db_frequencies=Allele frequencies in public databases are > 0.01 (filter_vcf).
##FILTER=fv.somca_depth_norm=Sequencing depth normal is too low < 100 (filter_vcf).
##FILTER=fv.somca_depth_tum=Sequencing depth tumor is too low < 100 (filter_vcf).
##FILTER=s.special_chromosome=Special chromosome.
##DESCRIPTION=CGI_drug_assoc=Cancer Genome Interpreter - therapeutic biomarkers
##DESCRIPTION=CGI_evid_level=Cancer Genome Interpreter - evidence level
##DESCRIPTION=CGI_transcript=Cancer Genome Interpreter - transcript to use
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	snp_q	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	gnomAD	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	ihdb_hom	ihdb_het	ihdb_wt	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info	som_ihdb_c	som_ihdb_p	CGI_drug_assoc	CGI_evid_level	CGI_transcript
chr6	39936849	39936849	A	-	0.3333	15	0.0000	34	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;fv.somca_db_frequencies	53	RP1-278E11.3-TUBBP9	intergenic_region	RP1-278E11.3-TUBBP9:ENSG00000180211-ENSG00000220586:intergenic_region:MODIFIER::n.39936849delA:						rs368059278	0.0990415	0.0000	0.0000														0	0					RP1-278E11.3-TUBBP9 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr7	81381340	81381340	G	T	0.1915	94	0.0000	197	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum	148	HGF	3_prime_UTR_variant,intron_variant,non_coding_transcript_exon_variant	HGF:ENST00000423064:3_prime_UTR_variant:MODIFIER:exon5/5:c.*88C>A:,HGF:ENST00000222390:intron_variant:MODIFIER:exon5/17:c.625+96C>A:,HGF:ENST00000457544:intron_variant:MODIFIER:exon5/17:c.610+96C>A:,HGF:ENST00000444829:intron_variant:MODIFIER:exon5/7:c.625+96C>A:,HGF:ENST00000453411:intron_variant:MODIFIER:exon5/7:c.610+96C>A:,HGF:ENST00000465234:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.734C>A:		Cytokine-cytokine receptor interaction;Focal adhesion;Renal cell carcinoma;Melanoma	Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization	Signaling of Hepatocyte Growth Factor Receptor			0.0000	0.0000	0.0000		147620 [HGF (confirmed) Rheumatoid arthritis,systemic juvenile,604302|Kaposi sarcoma,susceptibility to,148000|Diabetes,susceptibility to,222100,125853|Intracranial hemorrhage in brain cerebrovascular malformations,susceptibility to,108010|Crohn disease-associated growth failure,266600]:142409 [HGF (confirmed) Deafness,autosomal recessive 39,608265];												0	0					HGF (inh=AR pLI=0.99)	1	SomaticAndTreatment,	HGF	Pre-clinical	
chr8	59338990	59338990	A	G	0.2800	51	0.0000	96	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	126	UBXN2B,RP11-114M5.1	intron_variant	UBXN2B:ENST00000399598:intron_variant:MODIFIER:exon2/7:c.189-4088A>G:,RP11-114M5.1:ENST00000510501:intron_variant:MODIFIER:exon1/1:n.177+78T>C:,UBXN2B:ENST00000522978:intron_variant:MODIFIER:exon3/6:n.289-4088A>G:,UBXN2B:ENST00000520732:intron_variant:MODIFIER:exon2/5:c.189-6729A>G:,UBXN2B:ENST00000523409:intron_variant:MODIFIER:exon2/8:c.189-4088A>G:,UBXN2B:ENST00000521796:intron_variant:MODIFIER:exon1/4:c.24-4088A>G:			Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BET1L. VCPIP1 is also required, but not its deubiquitinating activity			rs577875541	0.000199681	0.0000	0.0000														0	0					UBXN2B (inh=n/a pLI=0.49), RP11-114M5.1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr10	104859659	104859659	G	C	0.1791	201	0.0000	358	fv.not_cod_spli	222	NT5C2	intron_variant	NT5C2:ENST00000343289:intron_variant:MODIFIER:exon8/17:c.633+24C>G:,NT5C2:ENST00000404739:intron_variant:MODIFIER:exon7/16:c.633+24C>G:,NT5C2:ENST00000369857:intron_variant:MODIFIER:exon9/18:n.817+24C>G:,NT5C2:ENST00000423468:intron_variant:MODIFIER:exon7/16:c.546+24C>G:,NT5C2:ENST00000452156:intron_variant:MODIFIER:exon9/10:c.657+24C>G:,NT5C2:ENST00000461461:intron_variant:MODIFIER:exon9/10:c.*505+24C>G:,NT5C2:ENST00000458345:intron_variant:MODIFIER:exon6/7:c.426+24C>G:,NT5C2:ENST00000470228:intron_variant:MODIFIER:exon4/4:n.298+24C>G:,NT5C2:ENST00000552185:intron_variant:MODIFIER:exon6/6:c.*156+24C>G:		Purine metabolism;Pyrimidine metabolism;Nicotinate and nicotinamide metabolism	May have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases. Preferentially hydrolyzes inosine 5'-monophosphate (IMP) and other purine nucleotides				0.0000	0.0000	0.0000		600417 [NT5C2 (provisional) Spastic paraplegia 45,autosomal recessive,613162];												0	0					NT5C2 (inh=AR pLI=0.05)	1	SomaticAndTreatment,			
chr12	12339935	12339935	C	T	0.1395	301	0.0000	402		220	LRP6,BCL2L14	missense_variant,intron_variant,non_coding_transcript_exon_variant	LRP6:ENST00000261349:missense_variant:MODERATE:exon4/23:c.766G>A:p.Glu256Lys,LRP6:ENST00000538239:missense_variant:MODERATE:exon3/24:c.358G>A:p.Glu120Lys,LRP6:ENST00000543091:missense_variant:MODERATE:exon4/23:c.766G>A:p.Glu256Lys,BCL2L14:ENST00000298566:intron_variant:MODIFIER:exon5/6:c.*25-304C>T:,LRP6:ENST00000545658:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.240G>A:	Six-bladed_beta-propeller__TolB-like__1_	Wnt signaling pathway	Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor- ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3- mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation (By similarity).,Plays a role in apoptosis				0.0000	0.0000	0.0000		603507 [LRP6 (confirmed) Coronary artery disease,autosomal dominant,2,610947|Tooth agenesis,selective,7,616724];			2.526000	D	T,T	B,B	D,D	16.43				0	0					LRP6 (inh=n/a pLI=1.00), BCL2L14 (inh=n/a pLI=0.14)	1	SomaticAndTreatment,			
chr13	28589177	28589177	A	C	0.1837	49	0.0000	94	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	98	FLT3	intron_variant	FLT3:ENST00000380982:intron_variant:MODIFIER:exon22/23:c.2762+117T>G:,FLT3:ENST00000241453:intron_variant:MODIFIER:exon22/23:c.2753+117T>G:,FLT3:ENST00000380987:intron_variant:MODIFIER:exon23/24:c.*665+117T>G:,FLT3:ENST00000537084:intron_variant:MODIFIER:exon21/22:c.2630+117T>G:		Cytokine-cytokine receptor interaction;Hematopoietic cell lineage;Acute myeloid leukemia	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways	Erythrocyte Differentiation Pathway			0.0000	0.0000	0.0000		136351 [FLT3 (confirmed) Leukemia,acute myeloid,reduced survival in,somatic,601626|Leukemia,acute myeloid,somatic,601626|Leukemia,acute lymphoblastic,somatic,613065];												0	0					FLT3 (inh=n/a pLI=0.61)	1	SomaticAndTreatment,	FLT3	Pre-clinical, Case report	
chr13	59104489	59104489	A	G	0.1875	112	0.0000	294	fv.not_cod_spli;fv.off_target	177	CTAGE16P	non_coding_transcript_exon_variant	CTAGE16P:ENST00000435601:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1741A>G:							0.0000	0.0000	0.0000														0	0					CTAGE16P (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr16	46386326	46386326	C	T	0.0794	63	0.0000	21	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	57	PPP1R1AP2-ANKRD26P1	intergenic_region	PPP1R1AP2-ANKRD26P1:ENSG00000261084-ENSG00000261239:intergenic_region:MODIFIER::n.46386326C>T:						rs28863908	0.0000	0.0000	0.0000														0	0					PPP1R1AP2-ANKRD26P1 (inh=n/a pLI=n/a)	3	SomaticAndTreatment,			
chr16	46389231	46389231	C	T	0.1778	45	0.0000	14	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	60	PPP1R1AP2-ANKRD26P1	intergenic_region	PPP1R1AP2-ANKRD26P1:ENSG00000261084-ENSG00000261239:intergenic_region:MODIFIER::n.46389231C>T:						rs4294836	0.0000	0.0000	0.0000														0	0					PPP1R1AP2-ANKRD26P1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr16	46391309	46391309	A	C	0.0261	269	0.0000	60	fv.not_cod_spli;fv.off_target;fv.somca_depth_norm;fv.somca_all_freq	63	PPP1R1AP2-ANKRD26P1	intergenic_region	PPP1R1AP2-ANKRD26P1:ENSG00000261084-ENSG00000261239:intergenic_region:MODIFIER::n.46391309A>C:						rs4378781	0.0000	0.0000	0.0000														0	0					PPP1R1AP2-ANKRD26P1 (inh=n/a pLI=n/a)	5	SomaticAndTreatment,TEST_SomaticAndTreatment,swift_protocol_test,			
chr16	46405144	46405144	T	-	0.0242	300	0.0000	72	fv.not_cod_spli;fv.off_target;fv.somca_depth_norm;fv.somca_all_freq	47	PPP1R1AP2-ANKRD26P1	intergenic_region	PPP1R1AP2-ANKRD26P1:ENSG00000261084-ENSG00000261239:intergenic_region:MODIFIER::n.46405144delT:						rs55698324	0.0000	0.0000	0.0000														0	0					PPP1R1AP2-ANKRD26P1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr16	66423388	66423388	G	A	0.2393	117	0.0000	339		232	CDH5	synonymous_variant,intron_variant	CDH5:ENST00000341529:synonymous_variant:LOW:exon5/12:c.744G>A:p.Leu248Leu,CDH5:ENST00000563425:synonymous_variant:LOW:exon4/6:c.744G>A:p.Leu248Leu,CDH5:ENST00000565334:intron_variant:MODIFIER:exon3/9:c.306-986G>A:		Cell adhesion molecules (CAMs);Leukocyte transendothelial migration	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction				0.0000	0.0000	0.0000														0	0					CDH5 (inh=n/a pLI=0.15)	1	SomaticAndTreatment,			
chr17	7577106	7577106	G	C	0.6330	109	0.0000	290		539	TP53	missense_variant,sequence_feature,intron_variant,non_coding_transcript_exon_variant	TP53:ENST00000269305:missense_variant:MODERATE:exon8/11:c.832C>G:p.Pro278Ala,TP53:ENST00000359597:missense_variant:MODERATE:exon7/9:c.832C>G:p.Pro278Ala,TP53:ENST00000420246:missense_variant:MODERATE:exon8/12:c.832C>G:p.Pro278Ala,TP53:ENST00000455263:missense_variant:MODERATE:exon8/12:c.832C>G:p.Pro278Ala,TP53:ENST00000445888:missense_variant:MODERATE:exon8/11:c.832C>G:p.Pro278Ala,TP53:ENST00000509690:missense_variant:MODERATE:exon5/6:c.436C>G:p.Pro146Ala,TP53:ENST00000420246:sequence_feature:LOW:exon8/12:c.832C>G:,TP53:ENST00000455263:sequence_feature:LOW:exon8/12:c.832C>G:,TP53:ENST00000445888:sequence_feature:LOW:exon8/11:c.832C>G:,TP53:ENST00000413465:intron_variant:MODIFIER:exon6/6:c.782+393C>G:,TP53:ENST00000504290:non_coding_transcript_exon_variant:MODIFIER:exon4/8:n.714C>G:,TP53:ENST00000504937:non_coding_transcript_exon_variant:MODIFIER:exon4/7:n.714C>G:,TP53:ENST00000510385:non_coding_transcript_exon_variant:MODIFIER:exon4/8:n.714C>G:	p53__DNA-binding_domain__1_,p53-like_transcription_factor__DNA-binding__1_,p53/RUNT-type_transcription_factor__DNA-binding_domain__1_	MAPK signaling pathway;Cell cycle;p53 signaling pathway;Apoptosis;Wnt signaling pathway;Amyotrophic lateral sclerosis (ALS);Huntington's disease;Colorectal cancer;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Basal cell carcinoma;Melanoma;Bladder cancer;Chronic myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer	Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis	Apoptotic Signaling in Response to DNA Damage;ATM Signaling Pathway;BTG family proteins and cell cycle regulation;Cell Cycle: G1/S Check Point ;Cell Cycle: G2/M Checkpoint;Chaperones modulate interferon Signaling Pathway;CTCF: First Multivalent Nuclear Factor;Double Stranded RNA Induced Gene Expression;Estrogen-responsive protein Efp controls cell cycle and breast tumors growth;Hypoxia and p53 in the Cardiovascular system;Overview of telomerase protein component gene hTert Transcriptional Regulation ;p53 Signaling Pathway;RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage;Regulation of cell cycle progression by Plk3;Regulation of transcriptional activity by PML;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility;Telomeres, Telomerase, Cellular Aging, and  Immortality;Tumor Suppressor Arf Inhibits Ribosomal Biogenesis		rs17849781	0.0000	0.0000	0.0000	COSM10814, COSM1646809, COSM99725, COSM3717626	191170 [TP53 (confirmed) Colorectal cancer,114500|Li-Fraumeni syndrome,151623|Hepatocellular carcinoma,114550|Osteosarcoma,259500|Choroid plexus papilloma,260500|Nasopharyngeal carcinoma,607107|Pancreatic cancer,260350|Adrenal cortical carcinoma,202300|Breast cancer,114480|Basal cell carcinoma 7,614740|Glioma susceptibility 1,137800];		CM120850 [CLASS=DM MUT=ALT PHEN="Breast cancer" GENE=TP53]; 	9.573000	D	D,D,D,D,D,D,D	D,D,D,D	D,D,D,D,D,D	27.20				0	0					TP53 (inh=AD pLI=0.91)	1	SomaticAndTreatment,	TP53	Early trials, Pre-clinical	, ENST00000269305
chr17	41276153	41276154	AT	-	0.0294	252	0.0049	478	fv.not_cod_spli;fv.off_target;fv.somca_all_freq	48	BRCA1	intron_variant	BRCA1:ENST00000471181:intron_variant:MODIFIER:exon1/23:c.-19-22_-19-21delAT:,BRCA1:ENST00000357654:intron_variant:MODIFIER:exon1/22:c.-19-22_-19-21delAT:,BRCA1:ENST00000309486:intron_variant:MODIFIER:exon1/21:c.-853-22_-853-21delAT:,BRCA1:ENST00000346315:intron_variant:MODIFIER:exon1/18:c.-19-22_-19-21delAT:,BRCA1:ENST00000352993:intron_variant:MODIFIER:exon1/21:c.-19-22_-19-21delAT:,BRCA1:ENST00000354071:intron_variant:MODIFIER:exon1/17:c.-19-22_-19-21delAT:,BRCA1:ENST00000468300:intron_variant:MODIFIER:exon1/21:c.-19-22_-19-21delAT:,BRCA1:ENST00000586385:intron_variant:MODIFIER:exon1/7:c.4+1045_4+1046delAT:,BRCA1:ENST00000591534:intron_variant:MODIFIER:exon1/10:c.-44+1134_-44+1135delAT:,BRCA1:ENST00000591849:intron_variant:MODIFIER:exon1/4:c.-99+1134_-99+1135delAT:,BRCA1:ENST00000493795:intron_variant:MODIFIER:exon1/21:c.-106-22_-106-21delAT:,BRCA1:ENST00000461221:intron_variant:MODIFIER:exon1/22:c.-19-22_-19-21delAT:,BRCA1:ENST00000491747:intron_variant:MODIFIER:exon1/22:c.-19-22_-19-21delAT:,BRCA1:ENST00000478531:intron_variant:MODIFIER:exon1/17:c.-19-22_-19-21delAT:,BRCA1:ENST00000493919:intron_variant:MODIFIER:exon1/16:c.-106-22_-106-21delAT:,BRCA1:ENST00000467274:intron_variant:MODIFIER:exon1/9:n.46-22_46-21delAT:,BRCA1:ENST00000470026:intron_variant:MODIFIER:exon1/9:c.-19-22_-19-21delAT:,BRCA1:ENST00000477152:intron_variant:MODIFIER:exon1/8:c.-19-22_-19-21delAT:,BRCA1:ENST00000492859:intron_variant:MODIFIER:exon1/10:c.-19-22_-19-21delAT:,BRCA1:ENST00000497488:intron_variant:MODIFIER:exon1/1:c.-219+1134_-219+1135delAT:,BRCA1:ENST00000494123:intron_variant:MODIFIER:exon1/9:c.-19-22_-19-21delAT:,BRCA1:ENST00000476777:intron_variant:MODIFIER:exon1/8:c.-19-22_-19-21delAT:,BRCA1:ENST00000461798:intron_variant:MODIFIER:exon1/6:c.-19-22_-19-21delAT:,BRCA1:ENST00000489037:intron_variant:MODIFIER:exon1/4:c.-19-22_-19-21delAT:		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8	ATM Signaling Pathway;BRCA1-dependent Ub-ligase activity;Cell Cycle: G2/M Checkpoint;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs564961882	0.0000	0.00026	0.00010		113705 [BRCA1 (confirmed) Breast-ovarian cancer,familial,1,604370|Pancreatic cancer,susceptibility to,4,614320];												0	0					BRCA1 (inh=AD pLI=0.00)	1	SomaticAndTreatment,	BRCA1	Early trials, FDA guidelines, Late trials, Pre-clinical, Case report	
chr17	61615414	61615414	C	T	0.6000	10	0.0000	51	fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	104	KCNH6	splice_region_variant&intron_variant	KCNH6:ENST00000583023:splice_region_variant&intron_variant:LOW:exon6/13:c.1502-12C>T:,KCNH6:ENST00000456941:splice_region_variant&intron_variant:LOW:exon7/13:c.1343-12C>T:,KCNH6:ENST00000581784:splice_region_variant&intron_variant:LOW:exon7/14:c.1343-12C>T:,KCNH6:ENST00000583465:splice_region_variant&intron_variant:LOW:exon6/12:c.*1171-12C>T:,KCNH6:ENST00000314672:splice_region_variant&intron_variant:LOW:exon6/12:c.1502-12C>T:			Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly			rs767994687	0.0000	0.00002	0.00002														0	0					KCNH6 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,			
